Immune checkpoint inhibitor (ICI) therapy uses monoclonal antibodies to boost the anti-cancer immune response by targeting the major immune checkpoint molecules: programmed cell death protein 1 (PD-1) and its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [7]. The gene discussed is CTLA4; the disease is cancer.